Therapeutic Potential of Imvotamab, a CD20-Targeted Bispecific IgM T Cell Engager, for the Treatment of Refractory Autoimmune Disease Patients

ACR Convergence 2023 — November 10-15, 2023

Reprinted from ACR Convergence held November 10-15, 2023. The American College of Rheumatology does not guarantee, warrant, or endorse any commercial products or services. Reprinted by IGM Biosciences.